Awakn Life Sciences Corp. (AWKNF)
| Market Cap | 2.78M |
| Revenue (ttm) | 41.02K |
| Net Income (ttm) | -1.59M |
| Shares Out | n/a |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,231 |
| Average Volume | n/a |
| Open | 0.0790 |
| Previous Close | 0.0790 |
| Day's Range | 0.0650 - 0.0849 |
| 52-Week Range | 0.0487 - 0.1700 |
| Beta | 2.60 |
| RSI | 37.99 |
| Earnings Date | Apr 25, 2025 |
About Awakn Life Sciences
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprie... [Read more]
News
Awakn Life Sciences Announces Shareholder Approval of Arrangement
Toronto, Ontario--(Newsfile Corp. - April 23, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), is pleased to announce that further to its press re...
Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement
Toronto, Ontario--(Newsfile Corp. - April 11, 2025) - Further to its press release dated February 27, 2025 and its management information circular dated May 10, 2025 (the "Circular"), Awakn Life Scien...
Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing...
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on...
Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - January 20, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing...
Awakn Life Sciences Announces Credit Facility
Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing th...
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc
Toronto, Ontario--(Newsfile Corp. - December 16, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing th...
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - December 10, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing t...
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing th...
Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Awakn Life Sciences Corp. (OTC: AWKNF), a clinical-stage biotechnology company, has announced a new partnership with the University of Nottingham to conduct in vivo testing of its aminoindane new che...
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing th...
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - October 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on dev...
Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing t...
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental...
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing ther...
Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
Toronto, Ontario--(Newsfile Corp. - July 31, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therap...
Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
Toronto, Ontario--(Newsfile Corp. - July 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing thera...
Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC
Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing thera...
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - June 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medicat...
CSE Bulletin: Reinstatement - Awakn Life Sciences Corp. (AWKN)
Toronto, Ontario--(Newsfile Corp. - Le 31 mai/May 2024) - Effective immediately, Awakn Life Sciences Corp. will be reinstated for trading. The Company has rectified the situation that gave rise to the...
Awakn Life Sciences Discusses Filing of Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medicat...
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
Awakn also announces Private Placement Toronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage ...
Canadian Securities Exchange Welcomes Listing of Awakn Life Sciences Corp
Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Awakn Life Sciences Corp., a clinical-stage biotechnol...
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)
Toronto, Ontario--(Newsfile Corp. - Le 9 février/February 2024) - The common shares of Awakn Life Sciences Corp. have been approved for listing on the CSE. Listing and disclosure documents will be ava...
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange
Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assist...